Written and maintained by CASRAI Editorial Board
Published
On this page
Title 21 of the Code of Federal Regulations, Section 314.50 (21 CFR 314.50), sets forth the mandatory content and format requirements for submitting a New Drug Application (NDA) to the United States Food and Drug Administration (FDA). Administered by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), this regulation defines the exact technical, clinical, nonclinical, and administrative sections applicants must assemble to demonstrate that a new drug is safe, effective, and manufactured to rigorous quality standards before commercial distribution in interstate commerce.
What it is and who runs it
Codified within Title 21 of the Code of Federal Regulations under Part 314, Subpart B, 21 CFR 314.50 serves as the operational blueprint for drug developers seeking marketing authorization under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. 355). It establishes the statutory criteria determining whether an application contains adequate technical documentation to warrant formal agency evaluation. Regulatory oversight is shared between two FDA centers: the Center for Drug Evaluation and Research (CDER), regulating chemical drugs and therapeutic biologics, and the Center for Biologics Evaluation and Research (CBER), regulating complex cellular therapies, vaccines, and blood products. As described on the official page on 2026-11-20, Section 314.50 governs original NDAs, formal amendments, resubmissions, and post-approval manufacturing supplements.
Section 314.50 operates within Title 21 of the Code of Federal Regulations as the commercial filing standard following investigational research under 21 CFR Part 312. Developers review the comprehensive FDA NDA overview to organize preclinical and clinical findings into this binding dossier framework.
What is an NDA submission?
An NDA submission, or New Drug Application submission, is the formal application through which a sponsor requests FDA approval to market a new pharmaceutical in the United States under Section 505(b) of the FD&C Act. Operationalized by 21 CFR 314.50, the application must provide evidence establishing that the drug is safe and effective for its proposed indications, therapeutic benefits outweigh risks, proposed labeling is truthful, and manufacturing controls conform to current Good Manufacturing Practice (cGMP) standards.
Are you legally obligated to comply with the FDA?
Compliance with FDA statutory mandates is legally binding under federal law for any entity marketing pharmaceuticals in interstate commerce. Under Section 505(a) of the FD&C Act (21 U.S.C. 355(a)), no new drug may be introduced into interstate commerce without an approved application. Distributing an unapproved drug or submitting false information exposes firms and corporate officers to federal injunctions, product seizures, import alerts, civil money penalties, and criminal prosecution under 21 U.S.C. 333. Adherence to 21 CFR 314.50 is the sole legally authorized mechanism to secure commercial marketing approval.
Eligibility and regulatory scope
The scope of 21 CFR 314.50 applies to pharmaceutical corporations, biotechnology companies, academic centers, and individual developers submitting marketing applications under the 21 CFR Part 314 regulatory framework. Applicants select either a standalone 505(b)(1) pathway relying on proprietary investigations or a hybrid 505(b)(2) pathway referencing published studies or FDA prior findings of safety and efficacy for a listed drug.
Section 314.50 also governs resubmissions following Complete Response Letters, substantial review amendments, and efficacy supplements. Foreign applicants must appoint an authorized United States agent who maintains a domestic business presence, countersigns Form FDA 356h, and accepts regulatory communications and legal service of process.
What 21 CFR 314.50 requires
The technical mandate of 21 CFR 314.50 is organized across twelve paragraphs designated from (a) through (l). As described on the official page on 2026-11-20, each section enforces distinct evidentiary requirements:
- Paragraph (a) – Application Form: Requires a completed and signed Form FDA 356h application form, providing applicant identity, product names, dosage form, strength, route of administration, IND and DMF cross-references, proposed indications, marketing category (Rx versus OTC), enclosure checklists, and authorized signatures.
- Paragraph (b) – Comprehensive Index: Mandates an index of all volumes and pages, implemented in electronic filings through structured XML backbone navigation.
- Paragraph (c) – Technical Summary: Requires a journal-quality scientific synthesis of draft labeling, pharmacological class, foreign marketing history, nonclinical data, human pharmacokinetics, clinical efficacy, and benefit-risk balance.
- Paragraph (d) – Technical Sections: Comprises seven specialized discipline sections: (1) Chemistry, Manufacturing, and Controls (CMC), documenting drug substance and product specifications, synthesis, impurities, batch records, packaging, and real-time stability datasets with proposed expiration dating; (2) Nonclinical Pharmacology and Toxicology, covering in vitro and animal safety pharmacology, pharmacokinetics, and systemic toxicity under Good Laboratory Practice (GLP, 21 CFR Part 58); (3) Human Pharmacokinetics and Bioavailability, documenting bioavailability, bioequivalence, and metabolic profiles; (4) Microbiology, required for anti-infectives to establish antimicrobial spectrum and resistance profiles; (5) Clinical Data, containing study reports, safety databases, and mandatory Integrated Summaries of Efficacy (ISE) and Safety (ISS); (6) Statistical Section, detailing statistical analysis plans, missing data strategies, and analysis datasets; and (7) Pediatric Use Section, providing pediatric assessments under PREA or documentation of approved pediatric study plans, deferrals, or waivers.
- Paragraph (e) – Samples and Labeling: Requires draft labeling conforming to the Physician Labeling Rule (PLR, 21 CFR 201.56/201.57), packaging labels, Medication Guides under 21 CFR Part 208, and physical drug samples upon request.
- Paragraph (f) – Case Report Forms and Tabulations: Mandates clinical data tabulations and individual Case Report Forms (CRFs) for subjects who died or discontinued due to adverse experiences.
- Paragraph (g) – Field Copy Certification: Requires certification that an identical copy of the CMC technical section was submitted to the relevant FDA district office.
- Paragraph (h) – Patent Information: Requires patent declarations on Form FDA 3542a for Orange Book listing.
- Paragraph (i) – Patent Certifications: Requires 505(b)(2) applications to include Paragraph I, II, III, or IV certifications or Section viii statements for listed patents.
- Paragraph (j) – Exclusivity Claims: Governs claims for 5-year NCE, 3-year clinical, orphan drug, or pediatric exclusivity.
- Paragraph (k) – Financial Disclosure: Demands clinical investigator financial disclosures on Form FDA 3454 or 3455 under 21 CFR Part 54.
- Paragraph (l) – Electronic Submission Format: Establishes electronic compilation standards under electronic Common Technical Document (eCTD) specifications.
What is the main purpose of 21 CFR Part 11?
The main purpose of 21 CFR Part 11 is to establish federal criteria under which the FDA considers electronic records, electronic signatures, and handwritten signatures executed to electronic records to be trustworthy, reliable, and equivalent to paper records and ink signatures. In the context of 21 CFR 314.50 compliance, Part 11 is critical because modern regulatory dossiers, analytical records, and clinical trial datasets are compiled and submitted electronically. Part 11 mandates computer system validation, secure time-stamped audit trails, user access controls, and digital signature integrity. Sponsors compiling an NDA must verify that clinical data capture tools, laboratory information management systems (LIMS), and eCTD compilation software satisfy Part 11 standards to ensure data integrity and avoid filing rejection.
Application and compliance steps
Filing an NDA under 21 CFR 314.50 requires navigating a structured sequential workflow spanning multi-year data integration, publishing, verification, and formal transmission. Applicants execute the following seven operational stages:
- Pre-Submission Engagement: Four to six months prior to submission, the sponsor attends a formal Pre-NDA meeting (PDUFA Type B) with the review division to align on clinical presentation, pediatric plans, and statistical analyses.
- eCTD Setup and Gateway Registration: Regulatory operations acquires a pre-assigned NDA number, sets up an FDA Electronic Submissions Gateway (ESG) account, and configures eCTD Modules 1 through 5.
- CMC Dossier Compilation (Module 3): Scientists compile drug substance and product specifications, batch manufacturing records, analytical validation, and stability datasets under ICH conditions per 314.50(d)(1).
- Nonclinical and Clinical Integration (Modules 4 and 5): Teams assemble GLP nonclinical study reports, CDISC SDTM and ADaM clinical datasets, and the mandatory Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) per 314.50(d)(5).
- Administrative and Legal Assembly (Module 1): Regulatory counsel executes Form FDA 356h, compiles patent declarations on Form FDA 3542a, reviews financial disclosures under 21 CFR Part 54, and drafts labeling conforming to the Physician Labeling Rule.
- Technical Validation and ESG Submission: The dossier is processed through validation tools to verify XML backbone integrity, functional hyperlinks, PDF/A compliance, and dataset integrity before secure transmission via the FDA ESG.
- Field Copy and Archive Management: Upon receiving ESG delivery receipts, the sponsor transmits field copy notifications to the FDA district office under 314.50(g) and archives the official electronic sequence.
What is section 415 of the FD&C Act?
Section 415 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350d) establishes the statutory requirement for the registration of food facilities. Enacted under the Bioterrorism Act of 2002 and amended by the FDA Food Safety Modernization Act (FSMA) in 2011, Section 415 requires domestic and foreign facilities that manufacture, process, pack, or hold food for consumption in the United States to register biennially. This provision is sometimes confused with pharmaceutical manufacturing registrations. For drug applications under 21 CFR 314.50, facility registration is governed not by Section 415, but by Section 510 of the FD&C Act (21 U.S.C. 360) and 21 CFR Part 207. When completing Form FDA 356h under 314.50(a), applicants list facilities registered under Section 510, reporting their FDA Establishment Identifier (FEI) and Dun and Bradstreet D-U-N-S numbers rather than food facility registrations.
Typical timeline phases
Once an NDA is submitted to the FDA under 21 CFR 314.50, the application enters a structured review lifecycle governed by statutory commitments under the Prescription Drug User Fee Act (PDUFA). Review timelines follow distinct operational phases:
- Filing Review Phase (Days 1 to 60): CDER or CBER conducts a mandatory 60-day filing review under 21 CFR 314.101. On or before Day 60, the FDA issues a filing determination. If accepted, the agency files the NDA and issues a Day 74 Letter communicating review classification (Standard 10-month versus Priority 6-month review). If the application is incomplete, the agency issues a Refusal to File (RTF) letter under 314.101(d).
- Substantive Technical Review Phase (Months 2 to 6): Multidisciplinary teams—including medical officers, toxicologists, chemists, and statisticians—evaluate the empirical evidence and issue formal Information Requests (IRs) requiring prompt sponsor responses.
- Mid-Cycle Communication and Advisory Committee Review (Months 5 to 7): The FDA holds a mid-cycle meeting to address significant review issues. For novel therapies or controversial risk-benefit profiles, the agency may convene an independent Advisory Committee meeting to solicit expert public guidance.
- Pre-Approval Facility Inspections (Months 3 to 8): Investigators from the FDA Office of Regulatory Affairs conduct on-site Pre-Approval Inspections (PAIs) of commercial manufacturing, packaging, and testing facilities to verify cGMP compliance and batch record authenticity.
- Labeling Negotiations and Postmarketing Commitments (Months 8 to 10): The agency and sponsor finalize the prescribing information, packaging graphics, and agreed postmarketing requirements and commitments (PMRs/PMCs).
- Action Letter Issuance: By the designated PDUFA goal date, the FDA issues an Approval Letter under 21 CFR 314.105 authorizing commercial marketing, or a Complete Response Letter (CRL) under 21 CFR 314.110 detailing deficiencies precluding approval.
Common mistakes and filing pitfalls
Failing to satisfy the structural and scientific standards of 21 CFR 314.50 carries severe operational consequences. Under 21 CFR 314.101(d)(3), the FDA reserves authority to refuse to file an application that is incomplete on its face. Common pitfalls triggering Refusal to File actions or review delays include:
- Administrative Deficiencies on Form FDA 356h: Incomplete manufacturing facility listings, omitted contract packaging sites, or absent countersignatures from authorized domestic United States agents for foreign sponsors under 314.50(a)(5).
- Defective Stability Datasets in CMC: Insufficient real-time primary stability data on production batches, missing accelerated storage data, or absent batch manufacturing records required by 314.50(d)(1)(ii).
- Omission of Integrated Summaries: Submitting individual clinical study reports without comprehensive, pooled cross-study analyses of safety (ISS) and efficacy (ISE).
- Pediatric Documentation Failures under PREA: Omitting an agreed initial Pediatric Study Plan (iPSP) or failing to submit a formal pediatric deferral or waiver request under 314.50(d)(7).
- Non-Compliant Electronic Datasets: Providing clinical or nonclinical data tabulations that fail to satisfy CDISC SDTM and ADaM standards or lack define.xml metadata files.
- Invalid Patent Declarations or Certifications: For 505(b)(2) filings, submitting defective Paragraph IV patent certifications or failing to provide timely statutory notice to patent owners under 21 CFR 314.52.
Related programs and regulatory pathways
The data table below compares the specific regulatory components across 21 CFR 314.50 paragraphs, their corresponding eCTD modules, and associated refusal-to-file risk factors. Beyond the core 314.50 framework, applicants navigate related regulatory mechanisms depending on molecule type and lifecycle stage. For post-approval changes, sponsors must follow 21 CFR 314.70 post-approval supplements to implement manufacturing modifications, new dosage forms, or expanded indications without invalidating their original approval.
The following table outlines comparative regulatory requirements across distinct FDA marketing application pathways:
| Regulatory Pathway | Statutory Authority | Primary Evidence Source | Patent Filing Requirements | Applicable Supplement Rule |
|---|---|---|---|---|
| Standalone NDA (505(b)(1)) | FD&C Act Section 505(b)(1); 21 CFR 314.50 | Full proprietary nonclinical and clinical investigation reports | Patent listing declarations on Form FDA 3542a (314.50(h)) | 21 CFR 314.70 (PAS, CBE-30, CBE-0, Annual Report) |
| Hybrid NDA (505(b)(2)) | FD&C Act Section 505(b)(2); 21 CFR 314.50 | Partial proprietary data plus published literature or FDA prior findings | Paragraph I-IV patent certifications or Section viii statement (314.50(i)) | 21 CFR 314.70 (PAS, CBE-30, CBE-0, Annual Report) |
| Abbreviated NDA (ANDA) | FD&C Act Section 505(j); 21 CFR 314.94 | Bioequivalence demonstration to Reference Listed Drug (RLD) | Paragraph I-IV patent certifications or Section viii statement (314.94(a)(12)) | 21 CFR 314.70 (applies to approved ANDAs) |
| Biologics License Application (BLA) | PHS Act Section 351; 21 CFR Part 601 | Proprietary data demonstrating purity, potency, and safety | Patent dance disclosures under BPCI Act (42 U.S.C. 262(l)) | 21 CFR 601.12 (changes to an approved BLA) |
Frequently asked questions
What is an NDA submission?
An NDA submission is a formal New Drug Application submitted to the FDA under Section 505(b) of the FD&C Act and 21 CFR 314.50. It serves as the primary scientific and regulatory mechanism for sponsors seeking approval to market a new chemical entity, new dosage form, or new clinical indication in the United States. The dossier contains comprehensive nonclinical, clinical, manufacturing, and statistical data demonstrating that the drug is safe and effective for its proposed use.
Are you legally obligated to comply with the FDA?
Yes. Any commercial organization or individual developer intending to manufacture, distribute, or market a human drug product in interstate commerce is legally obligated under federal law (21 U.S.C. 355) to obtain FDA approval before marketing. Introducing unapproved new drugs into commercial distribution constitutes a federal offense punishable by product seizures, federal court injunctions, import prohibitions, and criminal penalties.
What is the main purpose of 21 CFR Part 11?
The main purpose of 21 CFR Part 11 is to establish federal criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and legally equivalent to traditional paper records. In pharmaceutical development under 21 CFR 314.50, Part 11 requires rigorous computer system validation, secure electronic audit trails, user access controls, and electronic signature integrity across all electronic systems used to collect, analyze, and submit NDA data.
What is section 415 of the FD&C Act?
Section 415 of the FD&C Act (21 U.S.C. 350d) mandates biennial registration for domestic and foreign facilities that manufacture, process, pack, or hold food for human or animal consumption in the United States. It does not apply to pharmaceutical manufacturing sites. Drug manufacturing facilities included in an NDA under 21 CFR 314.50 are instead registered under Section 510 of the FD&C Act and 21 CFR Part 207, which requires establishment registration and drug listing.
What triggers a Refusal to File under 21 CFR 314.101?
The FDA issues a Refusal to File (RTF) letter under 21 CFR 314.101(d) when an application is incomplete on its face or fails to adhere to the formatting and content standards established in 21 CFR 314.50. Primary triggers include omitted primary stability data, absence of an integrated summary of safety or efficacy, non-validated electronic datasets failing CDISC specifications, or missing pediatric assessments under PREA.
Can an applicant submit a paper NDA under 21 CFR 314.50?
No. Under Section 745A(a) of the FD&C Act and binding FDA regulatory guidance, all commercial New Drug Applications must be submitted exclusively in electronic format using the electronic Common Technical Document (eCTD) standard through the FDA Electronic Submissions Gateway. Paper submissions are rejected upon receipt unless the applicant has applied for and secured a formal electronic submission waiver from the FDA.
Sources
- Electronic Code of Federal Regulations: 21 CFR 314.50 – Content and format of an NDA, checked 2026-11-20
- Cornell Law School Legal Information Institute: 21 CFR 314.101 – Filing an NDA and receiving an ANDA, checked 2026-11-20
- U.S. Food and Drug Administration: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications, checked 2026-11-20
- U.S. Food and Drug Administration: Forms — Form FDA 356h Application to Market a New or Abbreviated New Drug or Biologic for Human Use, checked 2026-11-20
Data: 21 CFR 314.50 Technical Component and eCTD Module Mapping Matrix
Comparative matrix mapping 21 CFR 314.50 regulatory sections to ICH electronic Common Technical Document (eCTD) modules, primary documentation mandates, and 21 CFR 314.101 filing risk factors.
Period covered: 2026. Coverage: United States.
| CFR Section | Component Name | eCTD Module | Statutory Focus | Filing Review Risk |
|---|---|---|---|---|
| 314.50(a) | Application Form | Module 1 (1.2) | Executed Form FDA 356h, establishment listings, and authorized US agent countersignature | Missing signed Form FDA 356h or absent US agent authorization for foreign sponsors |
| 314.50(c) | Technical Summary | Module 2 (2.2-2.7) | Comprehensive scientific synthesis of labeling, foreign marketing history, CMC, nonclinical, PK, and benefit-risk balance | Inadequate synthesis of data or omission of foreign regulatory marketing history |
| 314.50(d)(1) | Chemistry, Manufacturing, and Controls | Module 3 (3.2) | Drug substance and drug product specifications, synthesis, impurities, batch records, container closure, stability data | Incomplete primary batch stability data or unvalidated analytical methodology |
| 314.50(d)(2) | Nonclinical Pharmacology and Toxicology | Module 4 (4.2) | In vitro and in vivo animal pharmacology, safety pharmacology, pharmacokinetics, and pivotal GLP toxicology studies | Omission of required GLP compliant systemic or reproductive toxicity study reports |
| 314.50(d)(3) | Human Pharmacokinetics and Bioavailability | Module 5 (5.3.1-5.3.2) | In vivo bioavailability, bioequivalence, PK/PD relationships, metabolism, and dose-proportionality data | Absence of required human bioavailability data without an approved regulatory waiver |
| 314.50(d)(4) | Microbiology Section | Module 3 / Module 5 | Antimicrobial spectrum, mechanisms of action, resistance profiles, and clinical microbiology correlations for anti-infectives | Omission of antimicrobial susceptibility testing standards for anti-infective agents |
| 314.50(d)(5) | Clinical Data Section | Module 5 (5.3.5) | Integrated Summary of Efficacy (ISE), Integrated Summary of Safety (ISS), and complete Phase 1-3 clinical trial reports | Failure to provide pooled integrated safety datasets (ISS) or critical individual CRFs |
| 314.50(d)(6) | Statistical Section | Module 5 (5.3.5) | Statistical analysis plans, multiplicity adjustments, handling of missing data, and electronic CDISC analysis datasets | Missing CDISC SDTM or ADaM analysis datasets or unvalidated statistical analysis code |
| 314.50(d)(7) | Pediatric Use Section | Module 1 (1.3.4) | Pediatric assessment under PREA, initial pediatric study plan (iPSP), or approved deferral or waiver documentation | Omission of an agreed initial pediatric study plan (iPSP) or pediatric assessment documentation |
| 314.50(h) | Patent Information | Module 1 (1.3.5.1) | Patent declarations submitted on Form FDA 3542a for Orange Book listing of drug substance, product, or use claims | Missing Form FDA 3542a patent declarations or inaccurate patent claim listings |
| 314.50(i) | Patent Certification | Module 1 (1.3.5.2) | Paragraph I, II, III, or IV patent certifications or Section viii statement for 505(b)(2) applications | Defective Paragraph IV patent notice certification or invalid reference listed drug citation |
| 314.50(j) | Claimed Exclusivity | Module 1 (1.3.5.3) | Factual justifications for 5-year NCE, 3-year clinical, orphan drug, or pediatric exclusivity protection | Unsubstantiated exclusivity request or missing certification of active sponsor investigations |
| 314.50(k) | Financial Disclosure | Module 1 (1.3.4) | Clinical investigator financial disclosures submitted on Form FDA 3454 or Form FDA 3455 under 21 CFR Part 54 | Incomplete investigator financial disclosures or missing declarations for covered studies |
Sources
- Electronic Code of Federal Regulations: 21 CFR 314.50 - Content and format of an NDA (accessed 2026-11-20)
- Cornell Law School Legal Information Institute: 21 CFR 314.101 - Filing an NDA and receiving an ANDA (accessed 2026-11-20)
- U.S. Food and Drug Administration: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications (accessed 2026-11-20)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







